Jose Javier Vera Garcés

Advances in Cardiology and Nephrology: Diagnosis and Treatment provides an updated and integrated overview of cardiovascular and renal diseases. It highlights current diagnostic approaches, therapeutic strategies, and multidisciplinary management to support effective clinical decision-making and comprehensive patient care.

Modern Cardiovascular Imaging: Diagnosis and Clinical Decision-Making provides an updated overview of contemporary imaging techniques in cardiovascular medicine. It emphasizes diagnostic accuracy, image interpretation, risk assessment, and the integration of imaging findings into effective clinical decision-making and patient management.

Cardiology and Renal Disease: Diagnosis, Management and Prevention provides an integrated overview of the complex relationship between cardiovascular and renal disorders. It emphasizes early diagnosis, clinical assessment, therapeutic management, risk reduction, and preventive strategies to support comprehensive patient care.

Cardiology and Diagnostic Imaging: An Integrated Approach provides a concise and multidisciplinary overview of cardiovascular disease and modern imaging techniques. It integrates clinical assessment, imaging interpretation, diagnostic accuracy, and treatment planning to support effective cardiovascular care and informed clinical decision-making.

Introduction: Anti-N-methyl-D-aspartate receptor (NMDAr) encephalitis is a prevalent autoimmune condition marked by diverse neuropsychiatric symptoms, primarily impacting young females (Alzghoul et al., 2024). Approximately 38-40% of cases exhibit a paraneoplastic relationship, with ovarian teratomas being the most commonly associated malignancy (94% of tumor cases) (Vervloet Sollero et al., 2024; Alzghoul et al., 2024). The association between anti-NMDAr encephalitis and renal carcinoma is extremely rare, with isolated cases reported in the literature (Yang et al., 2020; Vervloet Sollero et al., 2024). Brugada syndrome is a cardiac channelopathy that predisposes to malignant ventricular arrhythmias and can be triggered by drugs, including those used in the management of encephalitis (Brugada et al., 2002). Objective: To synthesize the available evidence on anti-NMDA autoimmune encephalitis associated with renal adenocarcinoma and drug-induced Brugada syndrome. Methodology: Systematic review following PRISMA 2020 guidelines (Page et al., 2021). A systematic search was conducted in PubMed, LILACS, SciELO and Cochrane for studies published between 2000 and 2026 on anti-NMDA encephalitis, renal carcinoma and drug-induced Brugada syndrome. Results: Seven relevant studies documenting the association between anti-NMDA encephalitis and renal carcinoma were identified. Cases of young patients (20-54 years) with anti-NMDA encephalitis presenting clear cell renal carcinoma as underlying tumor were reported (Yang et al., 2020; Vervloet Sollero et al., 2024). Diagnosis was made through detection of anti-NMDAr antibodies in serum and CSF, and imaging studies revealing renal masses (Yang et al., 2020). Management included tumor resection, immunotherapy (corticosteroids, rituximab, cyclophosphamide) and plasmapheresis, with variable improvement of symptoms (Vervloet Sollero et al., 2024). The association with drug-induced Brugada syndrome has not been documented in the reviewed literature, but represents a potentially fatal complication requiring close electrocardiographic monitoring during immunosuppressive treatment (Brugada et al., 2002). Conclusion: Anti-NMDA encephalitis associated with renal carcinoma is an exceptional entity that requires a high index of suspicion and multidisciplinary management. Early diagnosis with imaging studies and antibody detection is essential to initiate timely immunosuppressive therapy and tumor resection. Electrocardiographic monitoring during treatment is essential to detect and manage drug-induced Brugada syndrome.